^
    Back
    Association details:
    Biomarker:EGFR exon 19 deletion + BRAF V600E
    Cancer:Lung Adenocarcinoma
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Tagrisso (osimertinib) (EGFR inhibitor) +
    Tafinlar (dabrafenib) (BRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    JTO Clin Res Rep
    Title:

    Pretreated EGFRdel19/ BRAFV600E Lung Adenocarcinoma With Leptomeningeal Disease Achieving Long-Lasting Disease Control on Osimertinib, Dabrafenib, and Trametinib: A Case Report

    Published date:
    08/03/2023
    Excerpt:
    We present the first reported case of a patient with pretreated EGFRdel19/BRAFV600E lung adenocarcinoma and symptomatic leptomeningeal metastasis obtaining durable clinical benefit on osimertinib, dabrafenib, and trametinib treatment.
    DOI:
    10.1016/j.jtocrr.2023.100545